Search Results

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization --Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like

If your team is designing covalent or tight-binding candidates, these principles reduce surprises and Designing for penetration —balance on/off rates to reach inner tissue, not just peripheries. Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters Jens Carlsson shares how structure-based design, molecular dynamics, and smart collaboration turn models Kenakin… sorely needed in the field." — DrGPCR University Attendee 🚀 Join now — and learn to design

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization

Evi Kostenis "Pharmacist by training - PhD in Pharmacology - Postdoc at the NIH with Dr. Pharmacology at 7TM Pharma in Denmark; Full professor, department chair and director of the institute for pharmaceutical

Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral

GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors GPCR About John Azietaku John Teye Azietaku,PhD is a trained pharmacist, holding a Ph.D. in Drug Discovery committed to leveraging his expertise to enhance healthcare outcomes and contribute to the growth of the pharmaceutical GPCR About Cam Sinh Lu Cam Sinh Lu is a PhD student at Monash Institute of Pharmaceutical Sciences, Monash